Finerenone, a selective mineralocorticoid receptor antagonist, has been proven to reduce albuminuria in patients with chronic kidney disease (CKD) and type 2 diabetes in previous trials. Recently, a clinical trial reported the long-term effects of finerenone on kidney and cardiovascular outcomes. A total of 5734 patients with CKD and type 2 diabetes were randomised to receive finerenone or placebo, with background renin–angiotensin system blockade treatment. The results showed that the rate of kidney failure or death from renal causes was reduced by 18% when compared finerenone aim to placebo aim. The rate of cardiovascular (CV) event or death from CV events was also reduced by 14%. Scientists concluded that finerenone may lower the risk of CKD progression and CV events with similar side effects as placebo.

Keyword: finerenone, chronic kidney disease, diabetes

Reference

Bakris GL, et al. N Engl J Med 2020; 383: 2219-2229.